US/UK/Canada

Share

Contacts

  • Ann Charlotte Svensson

    Investor Relations


    +46 70 285 72 62

    • Links

    Pick a time period -
    Tags ( Active)

    Gradientech: Interim report January–March 2026

    Gradientech AB (publ) interim report for Q1 2026 is now available on the company's website www.gradientech.se.First quarter 2026 · Net sales amounted to SEK 626 thousand (943). Please note that quarterly sales may vary as Gradientech's sales to distributors vary throughout the year. · Net profit/loss amounted to SEK -21,713 thousand (-18,950). · Earnings per share before and after dilution were SEK -0.67 (-0.63). · Cash flow from operating activities amounted to SEK -17,229 thousand (-19,916). · Cash and cash equivalents amounted to SEK 1,712 thousand (35,571) as of March

    Multicenter study shows QuickMIC delivers actionable AST results within the same shift

    Gradientech today announces the publication of a major European multicenter study demonstrating that its QuickMIC system can deliver rapid and reliable antibiotic susceptibility testing (AST) results within the same shift – up to 45 hours faster than conventional methods. The study highlights the transformative potential of ultra-rapid AST to improve sepsis management by enabling clinicians to make earlier, more informed treatment decisions.The prospective study was conducted across 12 hospitals in five countries including the United Kingdom, Germany, Sweden, Italy, and Portugal -

    Gradientech receives US patent allowance for its QuickMIC test

    Gradientech today announces having received a Notice of Allowance in the United States for its single-use microfluidic test, a key component of the CE marked QuickMIC system – the fastest diagnostic solution on the market for antibiotic susceptibility testing (AST) directly from blood cultures, enabling improved sepsis patient management.The U.S. Patent and Trademark Office has recognised the originality of the construction of the QuickMIC® test device design as part of the IVDR certified QuickMIC[®] solution by Gradientech. The U.S. patent application, based on International Publication

    Gradientech Reports Promising Interim Performance Data Including Cefiderocol for Expanded QuickMIC Gram-Negative Panel

    Gradientech today announces encouraging preliminary results from its ongoing performance study evaluating a second gram-negative panel for its rapid antimicrobial susceptibility testing (AST) system, QuickMIC[®], testing directly from positive blood cultures. The performance study includes reserve antimicrobials, including cefiderocol, targeting multidrug-resistant bacteria in the management of sepsis.The study, almost halfway completed, includes patient samples from three hospitals and covers six additional antibiotics, including cefiderocol, meropenem-vaborbactam, aztreonam-avibactam, and

    Gradientech publishes Annual Report for 2025

    Gradientech AB's Annual Report for 2025 has been published and is now available on the company's website.The Annual Report for 2025 is attached to this press release and can also be downloaded at www.gradientech.se For further information, please contact:Sara Thorslund, PhD, CEO          Tel: +46 736 29 35 80                  sara.thorslund@gradientech.se Urban Adolfsson, CFOTel: + 46 708 20 72 09urban.adolfsson@gradientech.se  About GradientechGradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious

    Gradientech Strengthens Momentum at ESCMID Global 2026 with Multiple Abstracts and Exhibition Presence

    Gradientech today announces a strong presence at ESCMID Global 2026, combining multiple abstract presentations with an active exhibition. At least six abstracts featuring its rapid antibiotic susceptibility testing system, QuickMIC®, have been accepted for presentation, highlighting the growing clinical interest, adoption, and validation of the technology.ESCMID Global, organised by the European Society of Clinical Microbiology and Infectious Diseases, is one of the most influential congresses in infectious diseases and clinical microbiology, bringing together over 16,000 professionals from

    Gradientech announces outcome of rights issue

    The diagnostics company Gradientech AB (publ) ("Gradientech" or the "Company") today announces the outcome of the new issue of shares with preferential rights for existing shareholders (the "Rights Issue") resolved by the Board of Directors on February 26, 2026. The final count in the Rights Issue shows that 5,619,127 shares, corresponding to approximately 87 percent of the Rights Issue, were subscribed for with and without the support of subscription rights. Through the Rights Issue, Gradientech will receive approximately SEK 49.2 million before deductions for issue costs, of which SEK 14

    Gradientech publishes prospectus

    The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue is approved by the Swedish Financial Supervisory Authority and is available on the Company's website gradientech.se .ProspectusComplete terms and conditions for the Rights Issue as well as other information about the Company and information about subscription commitments

    Gradientech carries out a rights issue of approximately SEK 57 million

    The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue will after approval by the Swedish Financial Supervisory Authority be available on the Company's website gradientech.se .Investor presentations Shareholders are invited to participate in Gradientech’s investor presentations via Teams at the following times: 11 March,

    Gradientech: Year-end report 2025

    Increased commercial traction and regulatory progress strengthen the foundation for continued expansionFourth quarter 2025 · Net sales amounted to SEK 2,548 thousand (1,194). Please note that quarterly sales may vary as Gradientech's sales to distributors vary throughout the year. · Net profit/loss amounted to SEK -18,072 thousand (-16,666). · Earnings per share before and after dilution were SEK -0.56 (-0.58). · Cash flow from operating activities amounted to SEK -16,805 thousand (-18,740). · Cash and cash equivalents amounted to SEK 6,965 thousand (24,596) as of December

    Gradientech Receives FDA Feedback on 510(k) Submission for QuickMIC

    The diagnostics company Gradientech today announces that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the company’s submitted 510(k) premarket notification for its QuickMIC[®] system for ultra-rapid antimicrobial susceptibility testing (AST) of bacterial isolates.Following submission of the 510(k) application and an initial period of interactive review, the FDA has issued a hold letter requesting additional information related to the application. The requested clarifications primarily relate to cybersecurity aspects of the system, as well as limited

    Gradientech Expands QuickMIC® Clinical Use in Germany

    The diagnostics company Gradientech, specialised in ultra-rapid antibiotic susceptibility testing (AST), today announces a long-term agreement with ELBLAB GmbH in Germany for the use of its QuickMIC® system. The agreement strengthens Gradientech’s presence in one of its key European markets and demonstrates its commitment to providing advanced diagnostic solutions to healthcare providers.ELBLAB GmbH, Meissen, is a centre for laboratory medicine responsible for all laboratory services within the ELBLAND Kliniken Group. ELBLAND Kliniken is a major regional healthcare provider in Saxony,

    Gradientech Partners with ELTA 90 MGR for Greece

    The diagnostics company Gradientech today announces that it has entered into an exclusive distribution agreement with ELTA 90 MGR for the commercialisation of the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) in Greece.The agreement marks another important step in Gradientech’s European expansion strategy and strengthens the company’s presence in Southern Europe. Through this partnership, QuickMIC® will be made available to Greek hospitals seeking faster, actionable AST results to support timely antibiotic decision-making in routine clinical practice. ELTA 90

    Gradientech distributor Iberlab wins significant tender for QuickMIC® in Portugal

    The diagnostics company Gradientech, together with its Portuguese distributor Iberlab, today announces the successful award of a direct tender for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) directly from positive blood culture samples.The Portuguese Hospital Unidade Local de Saúde da Guarda (ULS Guarda) has, following a direct tender procedure, selected QuickMIC® for integration into their clinical workflow for AST of sepsis samples. ULS Guarda is the principal public hospital serving the Guarda district and surrounding areas, delivering comprehensive acute

    Gradientech Submits QuickMIC® to the U.S. FDA for 510(k) Clearance

    The diagnostics company Gradientech today announces the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its QuickMIC[®] diagnostic system for ultra-rapid antimicrobial susceptibility testing (AST) of bacterial isolates.QuickMIC is currently the fastest phenotypic AST system on the market, delivering results within 2-4 hours directly from positive blood culture samples. This enables same-day optimisation of antibiotic therapy for sepsis patients — a critical improvement over traditional methods, which often take up to two days. The system is

    Gradientech Achieves Key Market Milestone as QuickMIC® Enters Routine Clinical Use in Austria

    The diagnostics company Gradientech and its distributor Biomedica Medizinprodukte, today announce the successful installation of the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) at the Wels-Grieskirchen Clinic in Austria, marking a pivotal step in the company’s European expansion.The Wels-Grieskirchen Clinic is Austria's largest hospital in the Wels region with 35 medical departments and more than 1,200 beds. The hospital is an essential provider of comprehensive medical care in Upper Austria. Through its competence centres, the hospital bundles interdisciplinary

    Gradientech: Interim report January–September 2025

    Gradientech AB (publ) interim report for Q3 2025 is now available on the company's website www.gradientech.se.Third quarter 2025 · Net sales amounted to SEK 1,517 thousand (829). Please note that quarterly sales may vary as Gradientech's sales to distributors vary throughout the year. · Net profit/loss amounted to SEK -14,990 thousand (-13,399). · Earnings per share before and after dilution were SEK -0.46 (-0.51). · Cash flow from operating activities amounted to SEK -14,640 thousand (-13,906). · Cash and cash equivalents amounted to SEK 24,667 thousand (13,142) as of

    Gradientech receives IVDR certification for QuickMIC[®]

    The diagnostics company Gradientech today announces that its QuickMIC[®] diagnostic test for ultra-rapid antibiotic susceptibility testing (AST) of sepsis samples, has been officially certified under the European Union’s In Vitro Diagnostic Medical Device Regulation (IVDR) – the new stringent regulatory framework for diagnostic devices.The IVDR is aimed at enhancing quality and ensuring safety by introducing more rigorous requirements for clinical performance, safety, and post-market surveillance, replacing the former European directive for In vitro diagnostic medical devices. The IVDR

    Global multicenter study: QuickMIC® proven 75% faster in sepsis diagnostics

    The diagnostics company Gradientech today announces a new scientific publication confirming the QuickMIC® system  to deliver accurate antibiotic susceptibility testing (AST) results up to 75% faster than current gold-standards automated solutions, enabling faster treatment decision for sepsis and blood stream infections. The clinical data is published in the high-ranked European Journal of Clinical Microbiology & Infectious Diseases.Conducted across four leading hospitals in Europe and the United States, the international multicenter study demonstrates that the QuickMIC ultra-rapid AST

    New study confirms QuickMIC[®] as fast and accurate targeting multidrug-resistant bacteria

    The diagnostics company Gradientech today announces the publication of a new peer-reviewed scientific study led by the renowned Italian research group of Professor Gian Maria Rossolini, showcasing the performance of the QuickMIC[®] system for ultra-rapid antibiotic susceptibility testing (AST).The study, conducted at the University of Florence and Careggi University Hospital, evaluated the performance of QuickMIC[®] in terms of both accuracy and time to results, comparing it with a standard-of-care workflow for AST. With Italy facing a high incidence of multidrug-resistant bacterial

    Gradientech: Interim report January–June 2025

    Gradientech AB (publ) interim report for Q2 2025 is now available on the company's website www.gradientech.se.Second quarter 2025 · Net sales amounted to SEK 881 thousand (1,948). Please note that quarterly sales may vary as Gradientech's sales to distributors vary throughout the year. · Net profit/loss amounted to SEK -20,272 thousand (-17,906). · Earnings per share before and after dilution were SEK -0.63 (-0.75). · Cash flow from operating activities amounted to SEK -21,085 thousand (-14,586). · Cash and cash equivalents amounted to SEK 40,100 thousand (6,750) as of June

    Gradientech wins Clinical Diagnostics Campaign of the Year

    The diagnostics company Gradientech today announces to have been awarded the Clinical Diagnostics Campaign of the Year at the prestigious Scientists’ Choice Awards® 2025, presented by SelectScience® during the ADLM 2025 (Association for Diagnostics & Laboratory Medicine) conference in Chicago, US.The award recognises Gradientech’s impactful and innovative campaign to raise awareness about its QuickMIC® ultra-rapid antibiotic susceptibility testing (AST) system, designed to support faster and smarter sepsis diagnostics. The winning campaign, produced in collaboration with SelectScience,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media